Intrust Bank NA Has $2.49 Million Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Intrust Bank NA lowered its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,391 shares of the medical equipment provider’s stock after selling 41 shares during the period. Intrust Bank NA’s holdings in Intuitive Surgical were worth $2,493,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. WCM Investment Management LLC bought a new position in Intuitive Surgical during the fourth quarter worth about $575,536,000. International Assets Investment Management LLC boosted its position in Intuitive Surgical by 32,360.5% during the fourth quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock worth $231,721,000 after purchasing an additional 684,749 shares during the period. Alphinity Investment Management Pty Ltd boosted its position in shares of Intuitive Surgical by 113.2% in the fourth quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock valued at $430,525,000 after acquiring an additional 677,455 shares during the period. J.P. Morgan Private Wealth Advisors LLC bought a new position in shares of Intuitive Surgical in the third quarter valued at approximately $178,667,000. Finally, Quadrature Capital Ltd boosted its position in shares of Intuitive Surgical by 466.2% in the third quarter. Quadrature Capital Ltd now owns 340,644 shares of the medical equipment provider’s stock valued at $99,601,000 after acquiring an additional 280,480 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Raymond James raised their price objective on shares of Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a research report on Thursday, January 25th. BTIG Research lifted their price target on shares of Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a research note on Friday, April 19th. Royal Bank of Canada lifted their price target on shares of Intuitive Surgical from $400.00 to $432.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 24th. Wells Fargo & Company lifted their price target on shares of Intuitive Surgical from $363.00 to $416.00 and gave the stock an “overweight” rating in a research note on Friday, January 19th. Finally, Truist Financial lifted their target price on shares of Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, January 24th. Five equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, Intuitive Surgical presently has an average rating of “Moderate Buy” and an average price target of $396.17.

Intuitive Surgical Stock Down 0.3 %

Shares of ISRG stock traded down $1.19 during mid-day trading on Monday, reaching $374.14. 921,634 shares of the company’s stock traded hands, compared to its average volume of 1,645,952. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $403.76. The company has a market cap of $132.71 billion, a P/E ratio of 67.75, a P/E/G ratio of 4.85 and a beta of 1.36. The company’s 50-day moving average price is $386.19 and its 200-day moving average price is $346.74.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.10. The firm had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. Intuitive Surgical’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.00 EPS. Equities analysts predict that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, Director Alan J. Levy sold 2,000 shares of the business’s stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total value of $741,400.00. Following the completion of the transaction, the director now owns 25,319 shares of the company’s stock, valued at approximately $9,385,753.30. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, President David J. Rosa sold 80,710 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $389.28, for a total transaction of $31,418,788.80. Following the completion of the sale, the president now owns 163,399 shares of the company’s stock, valued at approximately $63,607,962.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Alan J. Levy sold 2,000 shares of the company’s stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total transaction of $741,400.00. Following the sale, the director now directly owns 25,319 shares of the company’s stock, valued at approximately $9,385,753.30. The disclosure for this sale can be found here. Insiders sold a total of 225,093 shares of company stock valued at $87,153,299 in the last quarter. 0.80% of the stock is owned by insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.